New Study: Continuous Glucose Monitoring Improves Gestational Diabetes Outcomes

A 2025 multi-centre trial has provided compelling new evidence that continuous glucose monitoring (CGM) improves glycaemic control and reduces adverse outcomes in women with gestational diabetes, compared to traditional fingerstick self-monitoring. Given the notably high prevalence of gestational diabetes in the Gulf region, this research carries particular relevance for pregnant women across Dubai. As gestational diabetes prevalence across the UAE continues to sit well above global averages, technology that can genuinely improve glycaemic outcomes carries outsized importance for maternity care across the entire Emirate, not just for individual patients fortunate enough to access the newest monitoring tools.

What the Study Found
Women using CGM throughout their pregnancy achieved significantly more time within target glucose range compared to those using standard fingerstick monitoring, alongside reduced rates of large-for-gestational-age babies and neonatal hypoglycaemia — two of the most common complications associated with poorly controlled gestational diabetes.

Why This Matters in Dubai Specifically
Gestational diabetes affects an estimated 15 to 25% of pregnancies in the UAE — substantially above global averages — driven by elevated background rates of insulin resistance, obesity, and family history of type 2 diabetes among the region’s diverse population. This makes effective, accessible glucose monitoring technology particularly valuable for the large number of women managing GDM throughout the city, from Jumeirah to Downtown Dubai and beyond.

How CGM Changes Day-to-Day Management
Rather than requiring four to seven fingerstick tests per day, CGM provides continuous, real-time glucose data via a small sensor worn on the skin, allowing women and their care teams to identify patterns — such as specific foods or times of day associated with glucose excursions — that intermittent fingerstick testing often misses entirely.

What This Means for Your Antenatal Care
Women newly diagnosed with gestational diabetes in Dubai should discuss whether CGM is an appropriate option for their individual management plan. While fingerstick monitoring remains effective and is still appropriate for many women, this updated evidence supports CGM as a genuine, evidence-backed alternative for those who would benefit from more detailed glucose pattern data, particularly women requiring insulin therapy.

Cost and Access Considerations
Cost and access remain practical considerations alongside the clinical evidence — CGM sensors carry an ongoing cost that fingerstick testing supplies do not always match, and insurance coverage for CGM in gestational diabetes varies across providers in the UAE. Women considering this technology should discuss both the clinical benefits highlighted in this research and the practical logistics of access and cost with their obstetric team before deciding which monitoring approach best fits their pregnancy.
How This Compares to Current Standard Practice in Dubai

CGM technology is increasingly available across leading UAE hospitals and specialist obstetric clinics, though fingerstick monitoring remains the more universally accessible default option, particularly within standard insurance coverage frameworks across the Emirates.